Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 3Triple Negative Breast Neoplasms 2Melanoma 2Endometrial Neoplasms 2Breast Neoplasms 2Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1Endometrial Adenocarcinoma 1

Interventions

Cisplatin 3Taxes 2Paclitaxel 2Doxorubicin 2trastuzumab biosimilar HLX02 1trametinib 1pegfilgrastim 1nintedanib 1cediranib 1brivanib 1Trastuzumab 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1Medroxyprogesterone Acetate 1Medroxyprogesterone 1MK 2206 1Laparoscopy 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1GSK2141795 1Filgrastim 1Disulfides 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Endometrial Adenocarcinoma × GSK2141795 × Clear all
NCT01935973 2020-10-14

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

National Cancer Institute (NCI)

Phase 1 Completed
26 enrolled
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡